Published in Oncotarget on October 11, 2016
Reciprocal regulation of the cholinic phenotype and epithelial-mesenchymal transition in glioblastoma cells. Oncotarget (2016) 0.77
FEN1 promotes tumor progression and confers cisplatin resistance in non-small cell lung cancer. Mol Oncol (2017) 0.75
Knockdown of Tubulin Polymerization Promoting Protein Family Member 3 inhibits cell proliferation and invasion in human colorectal cancer. J Cancer (2017) 0.75
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Colorectal cancer. Lancet (2013) 5.40
Choline metabolism in malignant transformation. Nat Rev Cancer (2011) 2.85
Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol (2007) 2.35
Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res (2005) 2.11
Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun (2002) 2.09
Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene (2002) 2.09
RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res (2005) 1.77
Trends in cancer mortality in China: an update. Ann Oncol (2012) 1.72
Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res (2010) 1.65
Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res (2004) 1.53
Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res (2004) 1.49
Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn J Cancer Res (1999) 1.38
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res (2006) 1.29
Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. Oncogene (2009) 1.28
Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res (2007) 1.27
Improving the TNM classification: findings from a 10-year continuous literature review. Int J Cancer (2014) 1.27
Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res (2009) 1.27
Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules. Curr Med Chem (2012) 1.20
In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res (1999) 1.19
Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene (2004) 1.16
Regulation of Akt(ser473) phosphorylation by choline kinase in breast carcinoma cells. Mol Cancer (2009) 1.13
Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res (2005) 1.12
Choline kinase alpha and hexokinase-2 protein expression in hepatocellular carcinoma: association with survival. PLoS One (2012) 1.12
Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta (2014) 1.10
A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling. Oncogene (2011) 1.09
Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. Mol Cancer (2009) 1.09
A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas. Oncogene (2009) 1.09
Choline kinase: a novel target for antitumor drugs. IDrugs (2001) 1.05
MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients. Gastroenterology (2013) 1.05
The prognostic significance and therapeutic potential of hedgehog signaling in intrahepatic cholangiocellular carcinoma. Clin Cancer Res (2013) 1.05
Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells. NMR Biomed (2010) 1.03
Choline kinase alpha depletion selectively kills tumoral cells. Curr Cancer Drug Targets (2008) 1.03
Functional interactions between Choline kinase α, epidermal growth factor receptor and c-Src in breast cancer cell proliferation. Oncogene (2011) 1.02
Involvement of human choline kinase alpha and beta in carcinogenesis: a different role in lipid metabolism and biological functions. Adv Enzyme Regul (2010) 1.02
Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer. Br J Cancer (2013) 0.96
Alterations of choline phospholipid metabolism in endometrial cancer are caused by choline kinase alpha overexpression and a hyperactivated deacylation pathway. Cancer Res (2014) 0.96
An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis. Oncogene (2015) 0.93
Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma. Oncotarget (2015) 0.92
Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. J Natl Cancer Inst (2015) 0.92
Hepatitis B virus X protein enhances cisplatin-induced hepatotoxicity via a mechanism involving degradation of Mcl-1. J Virol (2011) 0.91
Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts. PLoS One (2013) 0.90
Choline kinase and its function. Biochem Cell Biol (2010) 0.90
Balance of human choline kinase isoforms is critical for cell cycle regulation: implications for the development of choline kinase-targeted cancer therapy. FEBS J (2012) 0.89
A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation. J Cell Sci (2013) 0.88
Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer. Br J Cancer (2014) 0.87
Choline kinase inhibition induces exacerbated endoplasmic reticulum stress and triggers apoptosis via CHOP in cancer cells. Cell Death Dis (2013) 0.86
Preclinical characterization of RSM-932A, a novel anticancer drug targeting the human choline kinase alpha, an enzyme involved in increased lipid metabolism of cancer cells. Mol Cancer Ther (2014) 0.85
Reduced expression of Dicer11 is associated with poor prognosis in patients with nasopharyngeal carcinoma. Med Oncol (2013) 0.84
A20 suppresses hepatocellular carcinoma proliferation and metastasis through inhibition of Twist1 expression. Mol Cancer (2015) 0.84
Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma. Oncotarget (2015) 0.83
Dysregulated choline metabolism in T-cell lymphoma: role of choline kinase-α and therapeutic targeting. Blood Cancer J (2015) 0.83
Activation of M3 muscarinic receptor by acetylcholine promotes non-small cell lung cancer cell proliferation and invasion via EGFR/PI3K/AKT pathway. Tumour Biol (2015) 0.81
Phosphatidylcholine metabolism and choline kinase in human osteoblasts. Biochim Biophys Acta (2014) 0.81
Magnetic resonance spectroscopy for detection of choline kinase inhibition in the treatment of brain tumors. Mol Cancer Ther (2015) 0.81
A non-catalytic role of choline kinase alpha is important in promoting cancer cell survival. Oncogenesis (2013) 0.81
A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation. Oncotarget (2016) 0.80
Novel Small Molecule Inhibitors of Choline Kinase Identified by Fragment-Based Drug Discovery. J Med Chem (2016) 0.79
Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors. Mol Cancer Ther (2016) 0.79
The novel choline kinase inhibitor ICL-CCIC-0019 reprograms cellular metabolism and inhibits cancer cell growth. Oncotarget (2016) 0.79
Exploiting altered patterns of choline kinase-alpha expression on human prostate tissue to prognosticate prostate cancer. J Clin Pathol (2015) 0.79
Overexpression of SULT2B1b is an independent prognostic indicator and promotes cell growth and invasion in colorectal carcinoma. Lab Invest (2015) 0.78
Design, synthesis, crystallization and biological evaluation of new symmetrical biscationic compounds as selective inhibitors of human Choline Kinase α1 (ChoKα1). Sci Rep (2016) 0.76
A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg (2009) 1.97
Overexpression of SULT2B1b is an independent prognostic indicator and promotes cell growth and invasion in colorectal carcinoma. Lab Invest (2015) 0.78
Low tristetraprolin expression promotes cell proliferation and predicts poor patients outcome in pancreatic cancer. Oncotarget (2016) 0.78
Paraoxonase 3 inhibits cell proliferation and serves as a prognostic predictor in hepatocellular carcinoma. Oncotarget (2016) 0.75
Downregulation of DHRS9 expression in colorectal cancer tissues and its prognostic significance. Tumour Biol (2015) 0.75